Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Cell Therapy Using Adipose-Derived Stem Cells for Chronic Liver Injury in Mice.

Ohashi K., Matsubara Y., Tatsumi K., Kohori A., Utoh R., Kakidachi H.

Laboratory Study on Systemic / IV, published in Cell Med (2012) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cell Med (2012)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
28058188
PMCID
PMC5196934
DOI
10.3727/215517912912X639432
Citations
3

Abstract (original English)

The present study investigated whether transplantation of autologous adipose-derived stem cells (ASCs) administered into the systemic circulation of a mouse with chronic liver injury provides therapeutic efficacy in the absence of any undesirable side effects. The ASCs used were isolated from mice with the same genetic background as the recipient mice and expanded in vitro. For the induction of chronic liver injury, mice were repetitively administered twice a week with CCl 4 , a well-known hepatotoxin, for a period of 4 weeks. One day after the eighth dose of CCl 4 , ASC transplantation was performed by tail vein injection and subsequently followed by two additional doses of CCl 4 administration. The recipient mice were divided into four groups (vehicle control, 1.5×10 3 , 1.5×10 4 , and 1.5×10 5 ASCs per mouse). One day after the final CCl 4 administration, all mice were sacrificed to assess serum markers and liver histology. The level of serum markers for liver injury and hepatic function did not differ among the four groups. Similarly, no difference was observed in the liver histology between groups. Cell transplantation with ASCs in our model of chronic liver failure did not result in any observable side effects, but from our results, a single application of ASCs seems to be ineffective in improving liver injury.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research